What is a stock summary page? Click here for an overview.
Business Description
Edgewise Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US28036F1057
Description
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 99.26 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -14 | |||||
| 3-Year EPS without NRI Growth Rate | -8.3 | |||||
| 3-Year FCF Growth Rate | -9.4 | |||||
| 3-Year Book Growth Rate | -4.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -14.5 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 8.12 | |||||
| 9-Day RSI | 11.9 | |||||
| 14-Day RSI | 16.78 | |||||
| 3-1 Month Momentum % | 10.19 | |||||
| 6-1 Month Momentum % | -1.68 | |||||
| 12-1 Month Momentum % | 65.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 19.93 | |||||
| Quick Ratio | 19.93 | |||||
| Cash Ratio | 19.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.2 | |||||
| Shareholder Yield % | -19.71 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -28.93 | |||||
| ROA % | -27.61 | |||||
| ROIC % | -837.31 | |||||
| 3-Year ROIIC % | -637.75 | |||||
| ROC (Joel Greenblatt) % | -1330.94 | |||||
| ROCE % | -34.05 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.37 | |||||
| Price-to-Tangible-Book | 2.37 | |||||
| EV-to-EBIT | -4.91 | |||||
| EV-to-EBITDA | -4.98 | |||||
| EV-to-FCF | -6.74 | |||||
| Price-to-Net-Current-Asset-Value | 2.43 | |||||
| Price-to-Net-Cash | 2.46 | |||||
| Earnings Yield (Greenblatt) % | -20.37 | |||||
| FCF Yield % | -9.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EWTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Edgewise Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.447 | ||
| Beta | 0.59 | ||
| 3-Year Sharpe Ratio | 0.62 | ||
| 3-Year Sortino Ratio | 1.43 | ||
| Volatility % | 59.41 | ||
| 14-Day RSI | 16.78 | ||
| 14-Day ATR ($) | 2.300591 | ||
| 20-Day SMA ($) | 21.1165 | ||
| 12-1 Month Momentum % | 65.94 | ||
| 52-Week Range ($) | 10.6 - 38.12 | ||
| Shares Outstanding (Mil) | 105.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Edgewise Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Edgewise Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Edgewise Therapeutics Inc Frequently Asked Questions
What is Edgewise Therapeutics Inc(EWTX)'s stock price today?
The current price of EWTX is $11.49. The 52 week high of EWTX is $38.12 and 52 week low is $10.60.
When is next earnings date of Edgewise Therapeutics Inc(EWTX)?
The next earnings date of Edgewise Therapeutics Inc(EWTX) is 2025-05-09 Est..
Does Edgewise Therapeutics Inc(EWTX) pay dividends? If so, how much?
Edgewise Therapeutics Inc(EWTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers